Resilience Software Specialist Restrata Secures Growth Investment From SEP
13.2.2025 01:01:00 CET | Business Wire | Press release
Restrata, the operational resilience software and service provider to global enterprises, including some of the world’s largest energy and industrial companies, has raised investment from Scottish Equity Partners (SEP) to meet growing market demand.
The investment will support accelerated product development and AI-powered enhancements as well as expansion of existing operations in North America, Europe, and the Middle East.
Increased adoption of the London-based company’s resilienceOS platform, which helps enterprise clients protect their people, assets and operations globally, saw resilienceOS revenue surge more than 50% in 2024.
Enterprises are increasingly focused on people safety and operational resilience due to unprecedented levels of global uncertainty. In response, business leaders are seeking sophisticated technology to mitigate, manage, and respond to operational disruption while maintaining visibility and control over day-to-day operations. These threats range from localised industrial accidents and targeted physical security issues to large scale political instability and security risks, industrial and road safety, extreme weather and natural disasters, as well as organised crime or lone wolf attacks. Spend on solutions such as resilienceOS is growing rapidly, with the multi-billion-dollar market growing more than 10% each year.
The company has been serving the security and safety needs of organisations operating globally, including in high-risk locations, since 2006. Co-founders Chris St George (Chair) and Botan Osman (CEO) combined their technology, security, military and government experience to create a better way for companies to protect people and operations, powered by software.
“We built resilienceOS to solve the challenge of relying on fragmented security systems to protect people and operations,” said Botan Osman. “Security and resilience teams want to focus on what matters most and need software to act as a force multiplier. Customers, employees, and shareholders expect leaders to adopt technology that safeguards people and protects businesses.”
Chris St George added: “resilienceOS is changing the way the world’s largest companies manage safety and security. In particular, the bespoke functionality designed for the energy sector is transforming duty of care in remote, offshore and high-risk markets — ultimately protecting assets, preventing injury and saving lives.”
Customers now use resilienceOS to power global security operation centres (GSOCS) around the world, managing incidents and crises, protecting global travellers everywhere, enabling people safety, monitoring lone workers, and protecting assets.
“resilienceOS is a fully unified platform, with an open ecosystem, working from a common customer data set to more effectively respond to critical events as they happen. The unified and open nature of the platform is unique in the market, and is the key reason why some of the most complex global customers are now choosing resilienceOS,” Osman continued.
“We are delighted to be partnering with the Restrata team to help build on the business’ current momentum,” added Tim Ankers, Director at SEP. “The company has developed a strong product and international customer base. The market tailwinds are clear and Restrata’s resilienceOS product is uniquely placed to serve the increasingly sophisticated security needs of global enterprises.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212395778/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom